NH HB1734

Creates a new licensing framework for experimental treatment centers in New Hampshire, allowing facilities to provide treatments involving investigational drugs, biologics, or devices that have completed phase one clinical trials but are not yet FDA-approved

Requires centers to obtain authorization from the Department of Health and Human Services with fees of $2,500 initially and $1,250 annually for RSA 151-licensed facilities, or $10,000 initially and $5,000 annually for unlicensed entities

Mandates that centers have a New Hampshire-licensed physician as medical director and a scientific review board of at least 3 members to approve treatment protocols and manufacturing processes

Prohibits the Board of Medicine from taking action against physicians' licenses based primarily on recommendations for experimental treatments, and protects licensed facilities from state action for participating in authorized treatments

Requires licensed experimental treatment centers to allocate 2 percent of net annual profits toward free experimental treatments for qualifying New Hampshire residents or contributions to designated health-related state funds